Longform · policy·18 min read
Six months into Schedule III: who actually benefited?
An audit of who gained, who lost, and who is still waiting on federal guidance.
By Marta Olsen · May 20, 2026
News
8 articles
Policy, industry, culture, and science. We publish slowly and on purpose — every claim is dated and sourced, and op-eds are clearly marked so you can tell reporting from argument.
Featured
Hand-picked
Report · industry
New York investigates "lab shopping" among potency-inflating brands
State regulators are subpoenaing four brands accused of switching labs to chase higher THC numbers.
May 187 min
Report · science
A new study revisits myrcene's role at CB1 — and finds it does almost nothing alone
The paper challenges a decade of folk theory about the "couchlock" terpene.
May 128 min
Latest
5 more- Briefpolicy
Minnesota debates lifting its 5mg edibles cap
The DFL-led legislature is considering raising single-serving limits after retailer pushback.
May 223 min - Op-edculture
The case against printing THC% on the jar at all
It misleads consumers, distorts producer incentives, and tells you almost nothing about how the flower will feel.
May 1511 min - Longformculture
In Oaxaca, an indigenous cooperative is rewriting the smallholder model
A five-village cooperative has spent four years building a vertically integrated cannabis economy that bypasses cartels and exporters alike.
May 914 min - Reportindustry
How much of your pre-roll is shake? More than you think.
We pulled 30 pre-rolls from machine-packed lines across three states and tore them apart.
May 59 min - Reportscience
The endocannabinoid system across the lifespan: a new review consolidates 20 years of data
How CB1 expression changes from childhood through old age, and what that means for dosing.
Apr 3010 min
On the roadmap
Author pages, tag/topic pages, a listen-to-article voiceover, and an AI-generated outline for longform pieces are coming. For now, follow the newsletter for the weekly editor’s digest.